drugset / Trial / NCT00697541
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
RandomizedCrossoverQuadruple-blindTreatment
Summary
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
Timeline
- Start
- 2008-05
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | 0.1 mg | Topical |
| Subject | Brimonidine | Small molecule | 1.8 mg | Topical |